Vivani Medical, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vivani Medical, Inc. (VANI) on January 25, 2026. The filing discloses the entry into material definitive agreements regarding two concurrent capital raising transactions: a private placement and a registered direct offering of common stock.
Key Financial Metrics and Transaction Details
- Private Placement: Sale of 1,351,351 shares to an entity affiliated with Chairman Gregg Williams at $1.48 per share, generating gross proceeds of approximately $2.0 million.
- Registered Direct Offering: Sale of 1,689,200 shares via ThinkEquity LLC, generating gross proceeds of approximately $2.5 million before fees.
- Total Gross Proceeds: Approximately $4.5 million combined from both transactions.
- Transaction Costs: The Registered Offering includes a 7.0% cash fee to the placement agent and reimbursement of up to $125,000 for legal and other expenses. No fees were incurred for the private placement.
- Stock Price: The purchase price of $1.48 per share reflects the last reported sale price on January 23, 2026.
Material Changes and Agreements
The Company entered into a Share Purchase Agreement for the private placement and a Placement Agency Agreement for the registered direct offering. A material change involves the issuance of new shares, which will result in dilution to existing shareholders. Directors and officers have entered into 60-day lock-up agreements regarding the Registered Offering. The filing does not provide comparative financial data (revenue, profit, cash flow, or debt levels) as this is a transactional report rather than a periodic financial statement.
Guidance, Risks, and Unusual Items
The filing does not contain updated financial guidance or management commentary on operational outlook. The primary risk disclosed relates to the dilution of existing shareholders due to the issuance of new shares. The private placement shares are unregistered and subject to resale restrictions under Rule 506 of Regulation D. The Company relies on the exemption from registration for the private placement based on representations that the purchaser is an accredited investor acquiring shares for investment purposes only.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting the 7.0% placement fee and reimbursable expenses from the Registered Offering.
- Confirm the total number of shares outstanding post-closing to assess the dilution impact on existing shareholders.
- Review the full text of the Share Purchase Agreement (Exhibit 10.1) and Placement Agency Agreement (Exhibit 10.2) for any additional covenants or conditions.
- Monitor the Company's use of the approximately $4.5 million in raised capital as disclosed in future filings.